XtalGazer
AI-powered platform for crystal polymorph exploration and crystallization R&D.
Executive Summary
XtalGazer is XtalPi's best-in-class crystal polymorph explorer and crystallization R&D platform. It combines crystal structure prediction (CSP) technology with crystallization strategy recommendations, offering a comprehensive solution for solid-state research and crystal structure determination. The platform leverages proprietary artificial intelligence (AI) models, quantum physics, and extensive cloud computing resources to accelerate polymorph prediction calculations. This approach delivers higher hit rates and improved material and time efficiency compared to traditional methods, supporting pharmaceutical and material science research.
Use Cases
- Crystal polymorph exploration and prediction
- Crystallization strategy recommendation and optimization
- Solid-state research and material science development
- Crystal structure determination for challenging samples (e.g., using MicroED)
- Enhanced salt screening and form selection in drug development
Features
Intelligence
- Crystal Structure Prediction (CSP): Predicts stable and metastable crystal polymorphs using advanced AI and quantum physics algorithms.
- Crystallization Strategy Recommendation: Provides data-driven recommendations for optimizing crystallization conditions and solid-state form development.
- Polymorph Explorer: Enables comprehensive exploration of the polymorph landscape for target compounds.
Technical Specifications
- Architecture
- Cloud-native platform integrating AI, quantum physics, and computational chemistry for crystal structure prediction and solid-state research.
- Deployment
- SaaS
Infrastructure
- Cloud-based
AI/ML Stack
- Proprietary AI models
- Quantum Physics algorithms
- Machine Learning
About XtalPi
XtalPi is a publicly listed biotechnology company that leverages AI, quantum physics, and robotics to accelerate drug discovery and materials research. They provide integrated solutions to streamline R&D processes, reducing time and waste in developing new therapies.